Share Prices & Company Research

Market News

17 Feb 2021 | 07:52

AstraZeneca's breast cancer drug moves to early primary analysis

(Sharecast News) - AstraZeneca said the phase 3 trial for breast cancer drug Lynparza would move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).

The change comes after the IDMC concluded Lynparza crossed the superiority boundary for its primary endpoint of invasive disease-free survival versus placebo for patients, and recommended primary analysis now take place, AstraZeneca said on Wednesday.

Lynparza is being jointly developed and commercialised by AstraZeneca and Merck and has been used to treat more than 40,000 patients worldwide.

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.